Hidroclorotiazida y espironolactona reducen la hipertrofia de la pared aórtica en la hipertensión arterial experimental

aims: to determine and compare the effects of hydrochlorotiazide (hctz) and spironolactone (esp) on hypertrophy of the aortic wall in experimental hypertension. methods: this was a comparative study with 4 experimental groups. we used male. uninephrectomized sprague dawley rats (150 ± 10 grs) treated with des-oxycorticosterone acetate (doca, 100 mg/kg/week sbc) during 6 weeks. as controls uninephrectomized rats (sham) were used. starting from the third week with doca, two groups recived diuretics by gavage during 3 weeks. one group received hctz (6 mg/kg/ day) and other group received sp (100 mg/kg/day). at the end of the study, systolic blood pressure (sbp), body weight, heart weight and relative cardiac weight were measured. hypertrohy in the aortic wall was assessed by measuring the media thickness (mt), media area (ma), lumen area (la) and by the am/la ratio on hematoxyline-eosine stained cross sections. results: compared to the sham group, in the untreated hypertensive doca group, sbp and relative cardiac weight increased significantly (by 51% and 79%, respectively), ma increased by 44%, as well as mt (57%) and the am/la ratio (43%). both treatments (hctz and sp) reduced importantly and significantly sbp, relative cardiac mass as well as mt, ma and the am/la ratio at a similar extent and by mm hg. conclusion: besides the antihypertensive effect, both hydrochlorotiazide and spironolactone prevent and/or regress aortic wall hypertrophy in this experimental model of hypertension.